OSD
Pharmaceutical firms are adopting new approaches to drug development in response to the increased need for patient-centricity. From creating dosage forms that are easier to swallow to developing extended-release medicines to reduce the number of dosing occasions and increase adherence, there are many benefits to putting the patient and their specific needs at the centre of drug development.
Geriatrics represent the most important patient population to consider for patient-centric dosage forms.
In this roundtable with industry experts, Torkel Gren, senior director, science and technology officer, at Recipharm discusses how patient adherence rates can be improved. He also outlines the potential challenges that pharmaceutical companies may face when developing new drugs for larger markets.